The aim of the review is to highlight the principle of action, effectiveness and prospects for the development of targeted therapy in the treatment of patients with malignant neoplasms based on recent clinical studies. Thanks to the active study of tumor biology, specific target molecules have been discovered and it has become possible to target tumor cells with targeted drugs. Today, targeted drugs are used in the treatment of malignant tumors of various organs and continue to demonstrate their effectiveness, improve overall survival and progression-free time, compared with previous standards of treatment.

Objective. The purpose of this review is to highlight the pathophysiological mechanisms of the sequential formation of left ventricular hypertrophy (LVH), left ventricular dysfunction and chronic heart failure (CHF) in patients with hypertension (HTN), diagnostic and therapeutical issues of CHF with both reduced and preserved ejection fraction (EF). HTN is the main risk factor for cardiovascular diseases and is accompanied by damage of target organs, among which LVH is of particular importance. On the one hand, development of LVH is the consequence of increased load on the heart muscle and neurohumoral stimuli, and on the other hand, it is an independent risk factor for myocardial infarction, stroke, cardiac arrhythmias and CHF. HTN precedes newly developed heart failure in 91 % of patients with a predominance of CHF with a preserved EF according to the Framingham Heart Study. To date, different drugs can improve the prognosis of patients with HTN, CHF with reduced EF and to induce LVH regression. However, the issues of effective treatment of patients with CHF with preserved EF are still insufficiently studied.